{
  "version": "https://jsonfeed.org/version/1.1",
  "title": "NOVA-4 Evidence Atlas",
  "home_page_url": "https://nova4.dev/learn/",
  "feed_url": "https://nova4.dev/feed.json",
  "description": "Source-linked scientific education from the NOVA-4 research program.",
  "authors": [
    {
      "name": "Oliver Odusanya",
      "url": "https://nova4.dev"
    }
  ],
  "items": [
    {
      "id": "N4-EDU-EN-001",
      "url": "https://nova4.dev/learn/what-are-enkephalins/",
      "title": "What Are Enkephalins? Endogenous Peptide Signaling Explained",
      "summary": "A source-linked explanation of enkephalins, how these short peptides are produced and cleared, and why preserving a signal differs from adding a receptor agonist.",
      "content_text": "Enkephalins are short-lived signaling peptides made by the body. Understanding their production, receptors and rapid enzymatic clearance is the first step toward understanding an endogenous-first research strategy.\n\nA signal produced inside the body\nEnkephalins belong to the endogenous opioid-peptide system. The word endogenous matters: these peptides are synthesized and released by cells as part of normal biological signaling. They interact with opioid receptors, but they are not the same thing as an externally administered opiate or a long-lived receptor agonist. Their location, timing and concentration are shaped by the tissue that releases them.\n\nBecause enkephalins are peptides, their behavior is also different from many small molecules. They are assembled from amino acids, released in response to biological activity and then removed quickly. That short lifetime helps keep signaling local and time-limited. It also means that measuring only receptor affinity would miss a major part of the system: production and clearance determine how much endogenous signal is available.\n\nWhy the signal disappears quickly\nMultiple peptidases participate in enkephalin breakdown. Two commonly studied enzymes are neprilysin, abbreviated NEP, and aminopeptidase N, abbreviated APN. Experimental dual-inhibitor work shows why researchers often examine both enzymes together: blocking one clearance route does not necessarily close the other route. The relevant scientific object is therefore a network, not a single switch.\n\nPreserving a naturally released peptide is not equivalent to producing an unlimited signal. The body must first release the peptide, other clearance pathways remain, and the magnitude of any downstream response depends on exposure, tissue distribution and receptor context. These distinctions are why a mechanism diagram is useful for generating hypotheses but cannot certify a finished-product effect.\n\nPreservation is different from substitution\nA direct receptor agonist supplies an external molecule that activates a receptor according to that molecule's own exposure profile. A preservation strategy instead attempts to slow removal of a signal that the body has already produced. The two architectures can involve related receptor biology while differing substantially in chemistry, timing, distribution and the experiments needed to characterize them.\n\nThat distinction should be described precisely. Non-opiate does not automatically mean non-pharmacological, effective, non-sedating or safe. Each of those properties requires its own evidence. A useful explanation separates molecular origin, target mechanism, measured exposure, observed response and safety instead of compressing them into one marketing adjective.\n\nHow NOVA-4 serializes the question\nWithin the NOVA-4 research architecture, C1 is the enkephalin-preservation axis. Candidate identity, NEP activity, APN activity, selectivity, exposure and target engagement are represented as separate obligations. The design therefore records what a candidate is intended to do without silently upgrading that intention into a measured outcome.\n\nThis object-based approach makes the research replayable. A source supports a mechanistic proposition; an exact candidate carries a defined assay requirement; and a combination carries additional interaction requirements. If a measurement is absent, the corresponding proposition remains a design target. That separation is the foundation of an evidence-linked product program.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "en",
      "tags": [
        "what are enkephalins",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-EN-002",
      "url": "https://nova4.dev/learn/nep-apn-enkephalin-degradation/",
      "title": "NEP and APN: Mapping the Dual Enkephalin-Degradation System",
      "summary": "A technical guide to neprilysin, aminopeptidase N and the constructive evidence required to establish dual enkephalinase modulation for an exact candidate.",
      "content_text": "The phrase dual enkephalinase compresses a demanding measurement problem. NEP and APN are distinct enzymes, and a credible dual-modulation claim has to resolve activity, selectivity and exposure for both.\n\nTwo enzymes, two assay obligations\nNeprilysin and aminopeptidase N are zinc-dependent peptidases with different substrate preferences and broader biological roles. Calling a molecule a dual inhibitor therefore creates two independent potency obligations. Activity against NEP does not mathematically imply activity against APN, and activity reported for a related scaffold does not transfer automatically to a new exact molecular graph.\n\nA rigorous program starts with concentration-response measurements against purified human enzymes or qualified cellular systems. Vehicle controls, validated reference inhibitors, interference controls and orthogonal confirmation are necessary because aggregation, fluorescence interference or nonspecific metal binding can mimic inhibition. Each result must remain attached to the exact stereochemistry, salt form and analytical identity of the tested material.\n\nThe intersection is the real design space\nSingle-target lists are not enough for a dual mechanism. Constructively, the first candidate universe is the intersection of compounds with evidence against NEP and compounds with evidence against APN. Even that intersection is only a discovery index: records can arise from different assays, concentrations, preparations or confidence levels and may not demonstrate balanced activity in one controlled experiment.\n\nThe next filter is selectivity. Both enzymes process substrates beyond enkephalins, and related metallopeptidases can create off-target liabilities. A useful profile therefore includes potency ratios across an enzyme panel, time dependence, reversibility where relevant and evidence that the intended activity survives the actual biological matrix. The dual label is earned by the complete measurement tuple.\n\nExposure connects chemistry to biology\nAn active compound in a biochemical well may never reach the relevant tissue at an adequate unbound concentration. Solubility, permeability, protein binding, metabolic stability and clearance determine whether an in-vitro result can influence an in-vivo system. For peptide-preservation research, location matters because peripheral and central compartments need not produce the same response.\n\nTarget engagement must also be distinguished from a downstream outcome. Reduced enzyme activity, altered peptide concentration and a reported subjective or functional effect sit at different levels of the causal chain. Human STR-324 research illustrates why these layers should remain separate: a program can be scientifically informative even when pharmacodynamic or clinical signals are not straightforward.\n\nA constructive certificate for C1\nThe NOVA-4 compiler represents C1 qualification as a conjunction rather than a narrative. Exact identity, NEP activity, APN activity, orthogonal confirmation, selectivity, exposure, target engagement and combination compatibility must each resolve. One failing or absent predicate prevents the mechanism from being presented as a finished-product fact.\n\nThis representation is valuable beyond one molecule. It allows a laboratory to replace a design candidate with measured data without rewriting the surrounding logic. Every new observation changes a named proof object, the replay hash changes, and the public explanation can be regenerated from the newly certified state. The result is a traceable research system rather than a static claim.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "en",
      "tags": [
        "NEP APN enkephalin degradation",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-EN-003",
      "url": "https://nova4.dev/learn/what-does-faah-do/",
      "title": "What Does FAAH Do? From Lipid Turnover to Target Engagement",
      "summary": "Understand fatty acid amide hydrolase, endocannabinoid-related lipid turnover, irreversible inhibition, selectivity and why engagement alone cannot predict outcomes.",
      "content_text": "FAAH is an enzyme involved in the turnover of fatty-acid amides. It is experimentally tractable, but its history also shows why potency, proteome selectivity, distribution and clinical response must be evaluated separately.\n\nFAAH is an enzyme, not an experience\nFatty acid amide hydrolase, usually shortened to FAAH, breaks down several signaling lipids, including anandamide. The enzyme can be studied with purified-protein assays, activity-based probes, tissue measurements and changes in lipid concentrations. These measurements describe molecular events. They do not, by themselves, describe how a person will feel or whether a product will achieve a useful outcome.\n\nThat distinction matters because endocannabinoid-related language is often compressed into broad terms such as balance or tone. A rigorous description identifies the exact substrate, tissue, time point and intervention. It also states whether the observation is biochemical, cellular, animal or human. Without those coordinates, two statements that sound similar can carry very different evidentiary weight.\n\nPotency and duration are only the beginning\nPF-04457845 became an important reference because it demonstrated potent, orally bioavailable and selective FAAH inhibition. Covalent or irreversible mechanisms create special measurement requirements: occupancy can persist after circulating concentrations fall, so exposure, enzyme recovery and dose timing must be modeled together. A single concentration cannot describe the full pharmacology.\n\nSelectivity also requires more than a short receptor panel. Activity-based protein profiling can reveal interactions across enzyme families in native biological material. The BIA 10-2474 investigation showed why exact-compound profiling and metabolite analysis matter. Safety conclusions cannot be transferred from a target name or from another inhibitor that happens to share that target.\n\nTarget engagement did not guarantee clinical benefit\nIn a randomized osteoarthritis study, PF-04457845 produced extensive FAAH inhibition and increased fatty-acid amides, yet the reported clinical analgesic endpoint did not separate meaningfully from placebo. This is a high-value scientific result because it breaks a tempting but invalid implication: strong target engagement does not force a desired human outcome.\n\nThere are several possible points of separation. The selected condition may not depend sufficiently on the pathway; the relevant compartment may differ; biomarker change may not reach the necessary causal node; or the endpoint may respond differently than expected. The correct response is not to erase the mechanism, but to design experiments that identify which link in the chain holds.\n\nHow C2 is represented in NOVA-4\nC2 is a research axis, not a finished efficacy statement. The NOVA-4 object model assigns separate fields to exact identity, human FAAH potency, proteome selectivity, active metabolites, unbound tissue distribution, target engagement and factorial contribution when combined with C1 and C3. No one field substitutes for the others.\n\nThis decomposition makes the project easier to test and harder to overstate. A laboratory can deliver a measurement packet for one predicate, and the compiler can certify exactly what changed. Public educational material can then explain established FAAH biology while keeping candidate-specific outcomes tied to candidate-specific evidence.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "en",
      "tags": [
        "what does FAAH do",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-EN-004",
      "url": "https://nova4.dev/learn/mechanism-is-not-clinical-outcome/",
      "title": "Why a Biological Mechanism Is Not Yet a Clinical Outcome",
      "summary": "A rigorous map from molecular identity through target engagement, biomarkers, controlled comparison and human outcome, with examples from FAAH and enkephalinase research.",
      "content_text": "Mechanistic evidence can be strong and still stop short of demonstrating a useful human result. The solution is to serialize the causal chain and test each transition instead of allowing one result to stand in for the whole system.\n\nThe causal ladder\nA product hypothesis usually begins with molecular identity and proceeds through a sequence: the molecule reaches a tissue, engages a target, changes a downstream biomarker, alters a biological process and ultimately produces a meaningful human outcome. Each arrow is an empirical proposition. Chemistry can establish identity, but identity does not establish exposure; exposure does not establish engagement; and engagement does not establish benefit.\n\nWriting the ladder explicitly prevents category errors. An enzyme assay answers whether material inhibits an enzyme under specified conditions. A pharmacokinetic study answers where and for how long material is present. A controlled human study answers a different question about outcomes in a defined population. These results can support one another without becoming interchangeable.\n\nNegative transfer is scientifically valuable\nThe PF-04457845 trial is an unusually clear teaching example. Investigators observed the intended molecular pharmacology and associated lipid changes, but the clinical pain endpoint did not show the expected benefit over placebo. That does not make the enzyme measurements false. It demonstrates that the inference from those measurements to that outcome, condition and study design did not hold.\n\nFirst-in-human STR-324 work provides another reason to keep layers separate. Safety, pharmacokinetics and exploratory pharmacodynamics can be characterized even when a straightforward dose-dependent functional signal is absent. A disciplined development system preserves all of these findings and updates only the propositions they directly address.\n\nCombination systems add interaction terms\nWhen several components are combined, single-agent evidence is necessary but insufficient. Components can alter one another's exposure, metabolism, target occupancy or downstream response. The combination may be additive, sub-additive, antagonistic or synergistic. Those possibilities are not adjectives to select; they are models to compare against an experimentally measured response surface.\n\nA factorial design can estimate main effects and interactions while preserving controls. Concentration matrices, replicate agreement and prespecified selection rules reduce the chance that one attractive data point determines the result. Once a combination is selected, the exact selected material still requires integrated safety and human testing because a computational winner is not a clinical certificate.\n\nEvidence-matched communication\nThe same hierarchy should govern public communication. Established general biology can be described with source links. A design intention should be labeled as a design intention. Candidate-specific performance requires candidate-specific measurements, and comparative claims require a qualified active-comparator design. This is not weaker communication; it is information with a precise type.\n\nThe NOVA-4 distribution compiler enforces that type boundary before publication. Claims, evidence objects and surfaces are serialized together. If a statement requires human product evidence and no matching object exists, the compiler rejects the statement while allowing accurate educational material to proceed. That produces a scalable library without turning scale into evidentiary drift.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "en",
      "tags": [
        "mechanism versus clinical outcome",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-EN-005",
      "url": "https://nova4.dev/learn/what-non-opiate-means/",
      "title": "What “Non-Opiate” Means in a Molecular Research Program",
      "summary": "Separate chemical origin, receptor pharmacology, endogenous signaling, product category and measured performance when evaluating the phrase non-opiate.",
      "content_text": "Non-opiate is a useful chemical distinction, but it is not a complete product certificate. Rigorous evaluation separates origin, direct receptor activity, pathway modulation, evidence level and intended use.\n\nBegin with chemical identity\nOpiates are historically associated with alkaloids derived from opium, while opioid is a broader pharmacological term that can include natural, semisynthetic, synthetic and endogenous substances acting within opioid-receptor systems. Everyday language often mixes these words, so a technical program should state exactly which distinction it intends instead of relying on the label alone.\n\nThe first question is therefore structural: what exact molecular graph is present? The second is pharmacological: does that material directly activate classical opioid receptors at relevant concentrations? These questions require analytical identity and receptor-panel data. A name, source story or computational target prediction cannot substitute for either measurement.\n\nEndogenous signaling changes the architecture\nEnkephalins are produced by the body and participate in opioid-receptor signaling. A strategy aimed at slowing their enzymatic degradation is different from supplying a persistent external receptor agonist. The endogenous signal must first be released, and its spatial and temporal pattern continues to shape the response. This is the conceptual foundation of an enkephalin-preservation program.\n\nDifferent does not mean automatically effective or risk-free. Peptidases process multiple substrates, pathway modulation can have effects outside the intended tissue, and a candidate can interact with unrelated targets. The distinction identifies what should be measured next; it does not remove the need to measure it.\n\nCategory follows the complete article and intended use\nProduct category cannot be derived from the phrase non-opiate. Regulators examine the actual ingredients, manufacturing process, labeling, representations and intended use. Dietary-supplement structure/function language concerns support for normal body structure or function, while disease-treatment claims occupy a different boundary. Exact ingredient eligibility and evidence remain necessary regardless of branding.\n\nThe same molecule can also be discussed in different contexts. An academic page may explain receptor pharmacology; a development dossier may define an assay; and a consumer-facing product page may create an intended-use implication through its wording and presentation. A rigorous publishing system evaluates both explicit statements and the message created by their context.\n\nThe NOVA-4 declaration\nFor NOVA-4, non-opiate by design means that the architecture is not organized around an opium-derived ingredient or declared direct classical opioid-receptor agonist. C1 instead encodes a dual-enzyme preservation hypothesis involving endogenous enkephalins. C2 and C3 encode separate target hypotheses rather than additional opioid-receptor agonists.\n\nThe declaration is intentionally bounded. Direct receptor counterscreens, exact ingredient-category analysis, same-material manufacturing controls, integrated safety and human performance remain their own gates. By publishing the boundary alongside the design, NOVA-4 can explain what is genuinely novel without asking one phrase to carry conclusions it cannot establish.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "en",
      "tags": [
        "what does non opiate mean",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-EN-006",
      "url": "https://nova4.dev/learn/multi-axis-comfort-research/",
      "title": "Multi-Axis Product Research: Main Effects, Interactions and Gates",
      "summary": "See how a three-axis molecular hypothesis becomes an enumerable combination lattice with factorial testing, interaction analysis and fail-closed selection rules.",
      "content_text": "A combination is not made rigorous by having more ingredients. Rigor comes from assigning each component a measurable role, enumerating the full design space and testing interaction terms before selecting one exact composition.\n\nAssign one role before combining\nMulti-component development begins by defining why each component exists. A component without a distinct hypothesis adds complexity without adding interpretability. For NOVA-4, the abstract roles are enkephalin-preservation research, FAAH-related lipid-signaling research and oxytocin-receptor-context research. These are target assignments, not assumed human outcomes.\n\nEach assignment expands into measurable predicates: exact chemical identity, potency, selectivity, exposure, tissue distribution and a component-specific contribution endpoint. A component advances only when its data can be distinguished from the behavior of the other components. This prevents an attractive total score from hiding a nonfunctional or counterproductive element.\n\nEnumerate before selecting\nThe current NOVA-4 design lattice contains six C1 candidates, two C2 candidates and two C3 candidates. Their Cartesian product produces twenty-four exact triplets. Enumeration makes the selection universe explicit. A candidate cannot disappear because it produced an inconvenient result, and a preferred story cannot introduce an unregistered combination after analysis.\n\nWithin each triplet, a concentration matrix samples low, medium, high and control levels across the three axes. That creates sixty-four concentration cells before replication and controls. Bliss independence and highest-single-agent comparisons can describe different forms of interaction, while confidence intervals and replicate agreement determine whether an apparent difference is stable enough to interpret.\n\nSelection must be deterministic\nA deterministic selector states its ordering before seeing the result. It can require assay quality, component qualification, minimum combination effect, bounded antagonism and safety counterscreens, then break remaining ties with an explicit stable rule. The same input dataset must always produce the same winner and the same replay hash.\n\nDeterminism does not turn synthetic or simulated observations into physical measurements. It guarantees that the analysis is reproducible once authenticated observations exist. That distinction is central: software closes ambiguity in data handling, while laboratories close uncertainty about material behavior. Both are required for a complete combination program.\n\nThe integrated product gate\nAfter selection, the exact combination becomes a new test article. Interaction pharmacokinetics, impurity profiles, formulation stability, dose ordering and integrated safety may differ from the components considered separately. Human evaluation must use the same defined combination rather than an approximate blend or a substitute from the same chemical family.\n\nThe evidence compiler keeps these obligations connected. The combination ID binds its three component identities, source records, assay packet, statistical analysis and public communication state. A public page can explain the lattice today, while any future product-specific statement must point to the later evidence object that actually supports it.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "en",
      "tags": [
        "multi pathway comfort research",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-EN-007",
      "url": "https://nova4.dev/learn/supplement-structure-function-claims/",
      "title": "Structure/Function Claims and Evidence-Matched Supplement Language",
      "summary": "A practical explanation of structure/function language, intended-use signals, substantiation and how an evidence compiler can keep health communication correctly typed.",
      "content_text": "Supplement communication is not made compliant by replacing one medical word with a softer synonym. The complete message must describe a lawful category, remain truthful and stay within the scope of the supporting evidence.\n\nThe claim is the complete communicated message\nRegulators evaluate more than one isolated sentence. Product name, surrounding images, testimonials, comparisons, search keywords, page structure and calls to action can combine into an express or implied message. Replacing a disease term with wellness language does not solve the problem when the overall presentation continues to promise treatment or prescription-equivalent performance.\n\nA rigorous system therefore represents intended use as a structured object. It records the proposed statement, audience, placement, linked evidence, jurisdiction and neighboring content. The review question becomes reproducible: what would a reasonable reader understand, and does the evidence support that understanding at the required level?\n\nStructure/function is a defined category\nFDA describes structure/function claims as statements about the role of a nutrient or dietary ingredient in affecting the normal structure or function of the human body. General well-being statements can also exist within the dietary-supplement framework. The exact ingredient must still qualify for the category, and the statement must be truthful and non-misleading.\n\nThis framework differs from a claim to diagnose, treat, cure or prevent disease. The boundary is not created by a disclaimer alone. Wording, context and scientific support work together. Ingredient eligibility, manufacturing controls, label requirements and required notifications are separate obligations that remain even when the sentence itself fits a structure/function form.\n\nSubstantiation must match specificity\nFTC guidance focuses on competent and reliable scientific evidence and on the fit between evidence and the advertised message. A study on a different ingredient, dose, preparation, population or endpoint may provide useful background while failing to substantiate a specific finished-product claim. Mechanistic plausibility is not the same evidence type as a controlled human outcome.\n\nSpecificity raises the evidentiary burden because it narrows what the statement asks the evidence to establish. Comparative, quantitative, rapid-onset, safety and serious-condition claims each introduce additional propositions. An evidence graph should split these propositions rather than attaching one citation to a sentence that silently contains several different promises.\n\nCompile language from evidence, not evidence from language\nThe NOVA-4 publishing architecture starts with evidence objects carrying source class and scope. A general-mechanism source can support an educational explanation. An internal design object can support a statement about what the program intends to measure. Neither can be promoted automatically into a finished-product human-effect statement.\n\nThis direction of compilation scales cleanly. New languages, pages and partner materials inherit the same typed claim object instead of improvising translations. When a stronger evidence object is added, the permitted output can expand deliberately. The system increases distribution while preserving one evidentiary meaning across every surface.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "en",
      "tags": [
        "supplement structure function claims",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-EN-008",
      "url": "https://nova4.dev/learn/evidence-linked-product-engineering/",
      "title": "Evidence-Linked Product Engineering: From Source to Proof Object",
      "summary": "How exact identity, source provenance, typed claims, deterministic selection and replay hashes turn a product dossier into a machine-verifiable evidence graph.",
      "content_text": "A conventional dossier is read as prose. An evidence-linked product system preserves the prose for people while also representing identities, claims, sources, gates and transformations as machine-verifiable objects.\n\nGive every proposition an identity\nA source document may contain dozens of propositions with different scopes. Evidence-linked engineering separates them. Each claim receives an identifier, assertion class, evidence references and publication surfaces. Each source receives a canonical identity, source class and content hash. Each candidate receives an exact structural identity rather than a family name.\n\nThis decomposition allows a verifier to answer precise questions. Which source supports this sentence? Does it concern general biology or the exact product? Was the tested material the selected stereoisomer? Did a later file change after review? These questions become database operations and invariant checks instead of manual searches through a long narrative.\n\nUse types to prevent evidentiary promotion\nThe strongest protection is a type boundary. A preclinical mechanism object cannot satisfy a human product-effect requirement. An internal design specification can support what the program intends to test, but not what a user will experience. A regulatory source can define a process without proving that a particular ingredient has completed it.\n\nThe compiler evaluates these relationships before generating a page, feed, video script or partner asset. Invalid references, unsupported classes and prohibited comparative language fail the build. Because every channel consumes the same approved object, scale does not require thousands of independent copy reviews for statements that are semantically identical.\n\nHash the transformation\nSHA-256 provides a stable fingerprint for a source snapshot or generated object. The hash does not prove that a scientific proposition is true; it proves that the bytes being reviewed are the same bytes later replayed. This solves a different but important problem: silent changes between analysis, approval and publication.\n\nA complete build records the atlas hash, compiler certificate, content-object hashes and output-file hashes. An independent verifier can regenerate the artifacts and compare them byte for byte. When evidence changes, the source hash and every dependent artifact change, making the revision visible rather than allowing stale outputs to retain an old approval state.\n\nMeasure delivery without confusing signals\nDistribution data needs the same discipline. An HTTP request, browser render, engaged session, click, order and contribution dollar are different events. Counting one as another creates fictional scale. The NOVA-4 reach ledger gives each event a separate type and binds it to the exact content surface and content hash.\n\nThe capacity model remains separate from observations. It can prove that a production plan supplies the five billion annual impressions required by the one-billion-person reach equation, but the observed ledger alone determines what was delivered. This separation lets the organization plan aggressively while reporting actual reach with the same precision used for molecular evidence.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "en",
      "tags": [
        "evidence linked product engineering",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-ES-001",
      "url": "https://nova4.dev/es/aprender/que-son-las-encefalinas/",
      "title": "¿Qué Son las Encefalinas? Una Guía de Señalización Endógena",
      "summary": "Una explicación documentada de las encefalinas, su producción y degradación, y la diferencia entre preservar una señal endógena y añadir un agonista externo.",
      "content_text": "Las encefalinas son péptidos de señalización producidos por el organismo. Su vida breve, distribución local y degradación enzimática definen un sistema distinto de la administración de un agonista receptor externo.\n\nUna señal creada dentro del organismo\nLas encefalinas forman parte del sistema de péptidos opioides endógenos. Endógeno significa que las células producen y liberan estos péptidos como parte de la señalización biológica normal. Interactúan con receptores opioides, pero no son alcaloides derivados del opio ni equivalen a un agonista externo de larga duración. El tejido, el momento y la concentración de su liberación ayudan a determinar su función.\n\nComo son péptidos cortos, las encefalinas se comportan de manera distinta a muchas moléculas pequeñas. Se construyen a partir de aminoácidos, aparecen en respuesta a actividad biológica y se eliminan con rapidez. Esta vida breve ayuda a limitar la señal en tiempo y espacio. Por eso, medir solamente la afinidad de un receptor no describe el sistema completo.\n\nPor qué la señal dura poco\nVarias peptidasas participan en la degradación de las encefalinas. Dos enzimas estudiadas con frecuencia son la neprilisina, NEP, y la aminopeptidasa N, APN. Los trabajos experimentales con inhibidores duales muestran por qué se investigan juntas: reducir una vía de eliminación no elimina necesariamente la otra. El objeto científico pertinente es una red de procesos.\n\nPreservar un péptido liberado naturalmente no produce una señal ilimitada. Primero tiene que existir liberación endógena; otras rutas de eliminación continúan; y la respuesta depende de exposición, distribución y contexto receptor. Un diagrama de mecanismo puede organizar hipótesis, pero no certifica por sí solo el resultado de un producto terminado.\n\nPreservación no significa sustitución\nUn agonista directo aporta una molécula externa que activa un receptor según su propia exposición. Una estrategia de preservación intenta reducir la eliminación de una señal ya producida por el cuerpo. Ambas arquitecturas pueden relacionarse con biología opioide, pero difieren en química, duración, distribución y en las pruebas necesarias para caracterizarlas correctamente.\n\nLa distinción debe mantenerse precisa. Que una estrategia no use un opiáceo no demuestra automáticamente eficacia, ausencia de sedación o seguridad. Cada propiedad necesita evidencia específica. La comunicación útil separa origen molecular, mecanismo objetivo, exposición medida, respuesta observada y márgenes de seguridad.\n\nCómo NOVA-4 representa la pregunta\nDentro de la arquitectura de investigación NOVA-4, C1 es el eje de preservación de encefalinas. La identidad candidata, la actividad sobre NEP, la actividad sobre APN, la selectividad, la exposición y la ocupación del objetivo aparecen como obligaciones distintas. La intención de diseño queda registrada sin transformarse silenciosamente en un resultado medido.\n\nEste enfoque permite repetir y verificar el proceso. Una fuente apoya una proposición mecanística; un candidato exacto lleva requisitos de ensayo; y una combinación añade requisitos de interacción. Cuando falta una medición, la proposición correspondiente continúa siendo una meta de investigación, no una conclusión.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "es",
      "tags": [
        "qué son las encefalinas",
        "NOVA-4 evidence atlas"
      ]
    },
    {
      "id": "N4-EDU-ES-002",
      "url": "https://nova4.dev/es/aprender/mecanismo-no-es-resultado-clinico/",
      "title": "Por Qué un Mecanismo Biológico No Es un Resultado Clínico",
      "summary": "Un mapa riguroso desde identidad molecular y ocupación del objetivo hasta biomarcadores, comparación controlada y resultados humanos significativos.",
      "content_text": "La evidencia mecanística puede ser sólida sin demostrar todavía un beneficio humano. La solución es representar cada transición causal y medirla, en lugar de permitir que un resultado sustituya al sistema completo.\n\nLa escalera causal\nUna hipótesis de producto suele comenzar con la identidad molecular y continuar mediante una secuencia: la molécula alcanza un tejido, interactúa con un objetivo, cambia un biomarcador, modifica un proceso biológico y finalmente produce un resultado humano significativo. Cada flecha es una proposición empírica. Identidad no demuestra exposición, exposición no demuestra ocupación y ocupación no demuestra beneficio.\n\nEscribir la escalera de forma explícita evita errores de categoría. Un ensayo enzimático responde si un material inhibe una enzima bajo condiciones definidas. Un estudio farmacocinético responde dónde está el material y durante cuánto tiempo. Un estudio humano controlado evalúa resultados en una población específica. Ninguno de estos objetos es intercambiable.\n\nUna transferencia fallida también aporta conocimiento\nEl ensayo de PF-04457845 es un ejemplo especialmente claro. Los investigadores observaron la farmacología molecular esperada y cambios en lípidos relacionados, pero el criterio clínico de dolor no mostró el beneficio previsto frente al placebo. Esto no invalida las mediciones de la enzima; demuestra que la inferencia hacia ese resultado no se sostuvo en ese contexto.\n\nEl trabajo inicial en humanos con STR-324 ofrece otra razón para separar niveles. La seguridad, farmacocinética y farmacodinámica exploratoria pueden caracterizarse incluso cuando no aparece una señal funcional sencilla dependiente de la dosis. Un sistema disciplinado conserva cada hallazgo y actualiza solamente las proposiciones que ese hallazgo aborda.\n\nLas combinaciones añaden términos de interacción\nCuando se combinan varios componentes, la evidencia de cada agente es necesaria pero insuficiente. Un componente puede modificar exposición, metabolismo, ocupación o respuesta de otro. La combinación puede ser aditiva, subaditiva, antagonista o sinérgica. Estas posibilidades son modelos que deben compararse con una superficie de respuesta medida, no descripciones que se eligen antes del experimento.\n\nUn diseño factorial estima efectos principales e interacciones mientras conserva controles. Matrices de concentración, acuerdo entre réplicas y reglas de selección previamente especificadas reducen la posibilidad de que un único dato atractivo determine la conclusión. La composición exacta seleccionada todavía necesita evaluación integrada.\n\nComunicación ajustada a la evidencia\nLa misma jerarquía debe gobernar la comunicación pública. La biología general establecida puede explicarse con fuentes. Una intención de diseño debe presentarse como intención. El desempeño de un candidato requiere mediciones del candidato, y una comparación exige un diseño con comparador activo adecuado. Así, cada afirmación conserva un tipo preciso.\n\nEl compilador de distribución NOVA-4 aplica esta frontera antes de publicar. Afirmaciones, objetos de evidencia y superficies se representan juntos. Cuando una frase requiere evidencia humana del producto y no existe un objeto compatible, la frase se rechaza mientras el material educativo exacto puede avanzar.",
      "date_published": "2026-07-17T00:00:00Z",
      "language": "es",
      "tags": [
        "mecanismo versus resultado clínico",
        "NOVA-4 evidence atlas"
      ]
    }
  ]
}